ALK-Abelló — Major Shareholding Notification 2016

Jan 15, 2016

Copenhagen, 2016-01-15 17:34 CET (GLOBE NEWSWIRE) --

Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC /
OMX: ALK B / AKABY / AKBLF) has received notification from Invesco Limited,
that Invesco Canada Ltd. has reduced its ownership in ALK-Abelló A/S to below
5% of the share capital.

Invesco Canada Ltd. now owns 4.8% of the company share capital equivalent to
486,615 B shares.

                             ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 1,900 employees with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with MSD
(known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and Seqirus
(previously bioCSL) to commercialise sublingual allergy immunotherapy tablets
in North America, Japan, Russia, Australia and New Zealand, respectively. The
company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen.
Find more information at www.alk.net.